127 related articles for article (PubMed ID: 38702918)
1. Pharmacokinetics and Safety of Atogepant Co-administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
Boinpally R; Borbridge L; Wangsadipura V
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38702918
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial.
Boinpally R; Spaventa J; Chen K; Butler M
Clin Drug Investig; 2021 Jun; 41(6):557-567. PubMed ID: 33948911
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A4 inhibition/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults.
Boinpally R; Chen W; McGeeney D; Trugman JM
Pain Manag; 2023 Aug; ():. PubMed ID: 37650778
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
Boinpally R; McGeeney D; Borbridge L; Trugman J
Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1013-1021. PubMed ID: 37210713
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
[TBL] [Abstract][Full Text] [Related]
7. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
[TBL] [Abstract][Full Text] [Related]
8. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Ashina M; Tepper SJ; Reuter U; Blumenfeld AM; Hutchinson S; Xia J; Miceli R; Severt L; Finnegan M; Trugman JM
Headache; 2023 Jan; 63(1):79-88. PubMed ID: 36651532
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetic interactions and safety of atogepant coadministered with esomeprazole.
Boinpally R; Butler M; Rojo J; Borbridge L; Wangsadipura V; Papinska A
Pain Manag; 2023 Jun; 13(6):351-361. PubMed ID: 37424270
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M
J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625
[TBL] [Abstract][Full Text] [Related]
12. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
[TBL] [Abstract][Full Text] [Related]
13. P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
Bhardwaj R; Collins JL; Stringfellow J; Madonia J; Anderson MS; Finley JA; Stock DA; Coric V; Croop R; Bertz R
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):889-897. PubMed ID: 35304977
[TBL] [Abstract][Full Text] [Related]
14. Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.
Boinpally R; Jakate A; Butler M; Periclou A
Pain Manag; 2022 May; 12(4):499-508. PubMed ID: 34898273
[TBL] [Abstract][Full Text] [Related]
15. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
[TBL] [Abstract][Full Text] [Related]
16. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
Min KC; Kraft WK; Bondiskey P; Colón-González F; Liu W; Xu J; Panebianco D; Mixson L; Dockendorf MF; Matthews CZ; Boinpally R
Clin Transl Sci; 2021 Mar; 14(2):599-605. PubMed ID: 33142014
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Klein BC; Miceli R; Severt L; McAllister P; Mechtler L; McVige J; Diamond M; Marmura MJ; Guo H; Finnegan M; Trugman JM
Cephalalgia; 2023 Jan; 43(1):3331024221128250. PubMed ID: 36620892
[TBL] [Abstract][Full Text] [Related]
18. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
Schoedel KA; Pope LE; Sellers EM
Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
[TBL] [Abstract][Full Text] [Related]
19. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
Singh A; Balasundaram MK
Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
